) -- Welcome to the doubleheader FDA advisory panel live blog: The morning panel features

Aveo Oncology

(AVEO) - Get Report

and its kidney cancer drug tivozanib. In the afternoon session,

Delcath Systems


brings the Melblez liver-tumor therapy in front of the FDA's outside experts.

The panel experts will consider the efficacy and safety of tivozanib and Melblez and vote to recommend approval -- or not. The final approval decision rests with the FDA.

Expect trading in both Aveo and Delcath to be halted during their respective panel sessions. Both stocks have been under pressure this week on FDA reviews which raised concerns and questions about the clinical benefit and/or safety of




. It will be the job of Aveo and Delcath to counter these concerns and convince the panel members that their respective products deserve FDA approval.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on



Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.